Chun-Su Lee
Comptroller/Controller/Auditor chez NOVMETAPHARMA CO., LTD.
Fortune : 222 677 $ au 31/05/2024
Provenance du réseau au premier degré de Chun-Su Lee
Entité | Type d'entité | Industrie | |
---|---|---|---|
Public Company | Pharmaceuticals: Major | 11 | |
NovMetaHealth Co. Ltd.
NovMetaHealth Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of NovMetaPharma Co., Ltd., NovMetaHealth Co. Ltd. develops and manufactures products related to metabolic diseases. The company is based in Seoul, South Korea. The South Korean company was founded in 2016. Seon-Wook Hwang has been the CEO of the company since 2016. NovMetaHealth Co. was acquired by NovMetaPharma Co., Ltd. on March 10, 2022 for $12.61 million.
3
| Subsidiary | Pharmaceuticals: Major | 3 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Chun-Su Lee via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
The Trustees of Columbia University in The City of New York | College/University | Graduate Degree | |
DONGWON F&B CO., LTD. | Food: Major Diversified | Director/Board Member | |
École Polytechnique Fédérale de Lausanne | College/University | Corporate Officer/Principal | |
Pohang University of Science & Technology | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
University of Massachusetts | College/University | Doctorate Degree | |
Katholieke Universiteit Leuven | College/University | Doctorate Degree | |
Seoul National University | College/University | Doctorate Degree Doctorate Degree | |
Inha University | College/University | Graduate Degree | |
Hanyang University | College/University | Undergraduate Degree | |
Sogang University | College/University | Graduate Degree | |
Kyungpook National University | College/University | Corporate Officer/Principal | |
Handong Global University | College/University | Graduate Degree | |
Chung-Ang University | College/University | Graduate Degree | |
University of Ulsan | College/University | Corporate Officer/Principal | |
David Geffen School of Medicine | College/University | Undergraduate Degree | |
Mitobridge, Inc.
Mitobridge, Inc. BiotechnologyHealth Technology Mitobridge, Inc. operates as a biopharmaceutical company. It focuses on the development and discovery of products for mitochondrial function. The firm also offers treatments for genetic, metabolic, and neurodegenerative disorders as well as diseases and conditions of aging. The company was founded by Kazumi Shiosaki, Andrew Dillin, Ronald M. Evans, Johan Auwerx and Robert H. Horvitz in October 2011 and is headquartered in Cambridge, MA. | Biotechnology | Founder | |
Stritch School of Medicine | College/University | Undergraduate Degree | |
PNC Holdings Co. Ltd. | Chief Executive Officer | ||
Reamol Biomedical Consulting Sàrl LLC | Chief Executive Officer |
Statistiques
Internationale
Corée du Sud | 12 |
Etats-Unis | 6 |
Suisse | 3 |
France | 2 |
Belgique | 2 |
Sectorielle
Consumer Services | 16 |
Health Technology | 3 |
Consumer Non-Durables | 2 |
Opérationnelle
Director/Board Member | 13 |
Graduate Degree | 8 |
Undergraduate Degree | 8 |
Corporate Officer/Principal | 7 |
Doctorate Degree | 6 |
Relations les plus connectées
Insiders | |
---|---|
Johan Auwerx | 6 |
Seon-Wook Hwang | 4 |
Sang-Joon Kim | 4 |
Hoi-Yoon Jung | 4 |
Mun-Jin Song | 3 |
Gi-Eop Lee | 3 |
In-Gyu Lee | 3 |
Jong-Man Seol | 3 |
Gyung-Tae Kim | 3 |
Heon-Jong Lee | 2 |
Jae-Ryong Lee | 1 |
- Bourse
- Insiders
- Chun-Su Lee
- Connexions Sociétés